WHOCC
Postal address:
Norwegian Institute of Public Health
WHO Collaborating Centre for Drug Statistics Methodology
Postboks 222 Sk°yen
0213 Oslo
Norway

Visiting/delivery address:
Myrens verksted 6H
0473 Oslo
Norway

Tel:  +47 21 07 81 60
E-mail:
 
Copyright/Disclaimer

New ATCvet 5th levels 2024

 Updates included in the ATCvet Index valid from 2024.

ATCvet codeATCvet level name
QA01AB53chlorhexidine and cetylpyridinium
QA02BC51omeprazole, combinations
QA02BD17vonoprazan and amoxicillin
QA02BX16irsogladine
QA05AA05ursodoxicoltaurine
QA05AX06elafibranor
QA07FA03escherichia coli
QA10AE07insulin icodec
QA10BD28metformin and teneligliptin
QA10BD29sitagliptin and dapagliflozin
QA10BK08bexagliflozin
QA10XX01teplizumab
QA16AB26eladocagene exuparvovec
QA16AB27pabinafusp alfa
QA16AX23leriglitazone
QB01AC28limaprost
QB01AD13apadamtase alfa and cinaxadamtase alfa
QB01AF51rivaroxaban and acetylsalicylic acid
QB02BD15valoctocogene roxaparvovec
QB02BD16etranacogene dezaparvovec
QB02BX10concizumab
QB05XA19 1)calcium gluconate
QB05XA20 2)sodium selenite
QB06AX05exagamglogene autotemcel
QC01CA28centhaquine
QC01CX10omecamtiv mecarbil
QC02KN01aprocitentan
QC04AX33clazosentan
QC05AX06phenylephrine
QC05XX01beperminogene perplasmid
QC05XX90beraprost
QC09BX06perindopril, bisoprolol, amlodipine and indapamide
QC09BX07zofenopril and nebivolol
QC10AB12pemafibrate
QC10BX20rosuvastatin and telmisartan
QC10BX21rosuvastatin and perindopril
QD03AX16beremagene geperpavec
QD05AX06roflumilast
QD05AX07tapinarof
QD11AH10lebrikizumab
QD11AH11delgocitinib
QD11AH12nemolizumab
QD11AH92ilunocitinib
QD11AH93atinvicitinib
QG03DB91melengestrol
QG04BD15vibegron
QG04BX17sodium salicylate and methenamine
QH02AB18vamorolone
QH05AA05palopegteriparatide
QH05BX06evocalcet
QI07AM04snake venom antiserum
QI09AL09porcine rotavirus + escherichia + clostridium
QI10AB05moritella
QJ01DC52cefuroxime and beta-lactamase inhibitor
QJ01DD58cefixime and beta-lactamase inhibitor
QJ01DE51cefepime and beta-lactamase inhibitor
QJ05AE16ensitrelvir
QJ05AP13ravidasvir
QJ05AR28stavudine and lamivudine
QL01BC58decitabine, combinations
QL01EJ04momelotinib
QL01EK04fruquintinib
QL01EL04orelabrutinib
QL01EL05pirtobrutinib
QL01EX26sitravatinib
QL01EX27capivasertib
QL01FF11sugemalimab
QL01FF12serplulimab
QL01FF13toripalimab
QL01FX24teclistamab
QL01FX25mosunetuzumab
QL01FX26mirvetuximab soravtansine
QL01FX27epcoritamab
QL01FX28glofitamab
QL01FX29talquetamab
QL01FY03prolgolimab and nurulimab
QL01XK52niraparib and abiraterone
QL01XL08lisocabtagene maraleucel
QL01XL09tabelecleucel
QL01XL10nadofaragene firadenovec
QL01XL11lifileucel
QL01XX78navitoclax
QL01XX79eflornithine
QL01XX80imetelstat
QL02BA04elacestrant
QL02BX53abiraterone and prednisolone
QL03AA19eflapegrastim
QL03AB17sampeginterferon beta-1a
QL03AX22leniolisib
QL04AA90fuzapladib
QL04AC24mirikizumab
QL04AC25levilimab
QL04AE05etrasimod
QL04AF08ritlecitinib
QL04AG15divozilimab
QL04AG16rozanolixizumab
QL04AG90cirevetmab
QL04AJ06zilucoplan
QL04AJ07crovalimab
QL04AJ08iptacopan
QL04AJ09danicopan
QM01AE57naproxen and diphenhydramine
QM04AC51colchicine and probenecid
QM09AX14givinostat
QM09AX15delandistrogene moxeparvovec
QM09AX91polyacrylamide
QM09AX92canine stem cells
QN02AD51pentazocine and naloxone
QN02AJ22hydrocodone and paracetamol
QN02AJ23hydrocodone and ibuprofen
QN02BA67magnesium salicylate, combinations excl. psycholeptics
QN02CC51sumatriptan and naproxen
QN05CJ03daridorexant
QN06AX62bupropion and dextromethorphan
QN06DX04lecanemab
QN06DX05donanemab
QN07XX19sodium phenylbutyrate and ursodoxicoltaurine
QN07XX21eplontersen
QN07XX22tofersen
QN07XX23troriluzole
QR03AK15salbutamol and budesonide
QS01AA32bacitracin
QS01AX24polihexanide
QS01BA16difluprednate
QS01CA12loteprednol and antiinfectives
QS01HA08chloroprocaine
QS01XA31pegcetacoplan
QV03AB54pralidoxime and atropine
QV04CX11lithium chloride
QV09IA10technetium (99mTc) trofolastat chloride
1) Parenteral formulations should be classified here. Oral preparations should be classified in QA12AA03.
2) Parenteral formulations should be classified here. Oral preparations should be classified in QA12CE02.

Last updated: 2023-12-21